L Belardinelli

Summary

Affiliation: CV Therapeutics
Country: USA

Publications

  1. ncbi request reprint Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists
    Z Gao
    Department of Pharmacological Sciences, CV Therapeutics, Palo Alto, California 94304, USA
    J Pharmacol Exp Ther 298:209-18. 2001
  2. pmc Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine
    L Belardinelli
    Department of Pharmacological Sciences, CV Therapeutics, Inc, 3172 Porter Dr, Palo Alto, CA 94304, USA
    Heart 92:iv6-iv14. 2006
  3. ncbi request reprint Use of preclinical assays to predict risk of drug-induced torsades de pointes
    Luiz Belardinelli
    CV Therapeutics Inc, 3172 Porter Drive, Palo Alto, CA 94304, USA
    Heart Rhythm 2:S16-22. 2005
  4. ncbi request reprint Assessing predictors of drug-induced torsade de pointes
    Luiz Belardinelli
    CV Therapeutics, 3172 Porter Drive, Palo Alto, CA 94304, USA
    Trends Pharmacol Sci 24:619-25. 2003
  5. pmc Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium
    J C Shryock
    CV Therapeutics Inc, Palo Alto, CA 94304, USA
    Br J Pharmacol 153:1128-32. 2008
  6. doi request reprint Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats
    A K Dhalla
    Department of Pharmacological Sciences, CV Therapeutics, Inc, Palo Alto, CA 94304, USA
    Diabetes Obes Metab 11:95-101. 2009
  7. ncbi request reprint 2-substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor
    J Zablocki
    Tripos, Inc, San Francisco, California, USA
    Nucleosides Nucleotides Nucleic Acids 20:343-60. 2001
  8. pmc Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury
    Chun Xiao Sun
    Department of Biochemistry and Molecular Biology, University of Texas Medical School at Houston 77030, USA
    J Clin Invest 116:2173-2182. 2006
  9. ncbi request reprint Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists
    Ming Yang
    Department of Pharmacology, CV Therapeutics, Inc, Palo Alto, CA 94304, USA
    Naunyn Schmiedebergs Arch Pharmacol 375:133-44. 2007
  10. ncbi request reprint A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents
    Arvinder K Dhalla
    Department of Pharmacological Sciences, CV Therapeutics, Palo Alto, California, USA
    Am J Physiol Endocrinol Metab 292:E1358-63. 2007

Collaborators

Detail Information

Publications62

  1. ncbi request reprint Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists
    Z Gao
    Department of Pharmacological Sciences, CV Therapeutics, Palo Alto, California 94304, USA
    J Pharmacol Exp Ther 298:209-18. 2001
    ..Hence, the low-affinity A2A agonists CVT-3146 and CVT-3033 may prove to be superior to currently available high-affinity agonists as coronary vasodilators during myocardial imaging with radionuclide agents...
  2. pmc Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine
    L Belardinelli
    Department of Pharmacological Sciences, CV Therapeutics, Inc, 3172 Porter Dr, Palo Alto, CA 94304, USA
    Heart 92:iv6-iv14. 2006
    ..Thus, inhibition of late I(Na) can reduce [Na(+)](i)-dependent calcium overload and its detrimental effects on myocardial function...
  3. ncbi request reprint Use of preclinical assays to predict risk of drug-induced torsades de pointes
    Luiz Belardinelli
    CV Therapeutics Inc, 3172 Porter Drive, Palo Alto, CA 94304, USA
    Heart Rhythm 2:S16-22. 2005
    ..Current experimental models and protocols, especially those using conditions wherein the net repolarizing current is reduced, can detect the potential for a drug to induce TdP, even when the potential is extremely low...
  4. ncbi request reprint Assessing predictors of drug-induced torsade de pointes
    Luiz Belardinelli
    CV Therapeutics, 3172 Porter Drive, Palo Alto, CA 94304, USA
    Trends Pharmacol Sci 24:619-25. 2003
    ..The exact relationship between these electrophysiological events and the development of TdP has not been defined, but the potential of a drug to elicit these events might predict its pro-arrhythmic risk...
  5. pmc Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium
    J C Shryock
    CV Therapeutics Inc, Palo Alto, CA 94304, USA
    Br J Pharmacol 153:1128-32. 2008
    ....
  6. doi request reprint Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats
    A K Dhalla
    Department of Pharmacological Sciences, CV Therapeutics, Inc, Palo Alto, CA 94304, USA
    Diabetes Obes Metab 11:95-101. 2009
    ..The present study was undertaken to compare the antilipolytic effects of CVT-3619 in normal (Sprague Dawley, SD) and Zucker diabetic fatty (ZDF) rats...
  7. ncbi request reprint 2-substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor
    J Zablocki
    Tripos, Inc, San Francisco, California, USA
    Nucleosides Nucleotides Nucleic Acids 20:343-60. 2001
    ..4 +/- 1.2 nM and 67.9 +/- 16.7 nM, respectively), but they possess low affinity for the ADO A2A receptor (Ki = 1122 +/- 323 nM and 2138 +/- 952 nM, respectively; pig striatum)...
  8. pmc Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury
    Chun Xiao Sun
    Department of Biochemistry and Molecular Biology, University of Texas Medical School at Houston 77030, USA
    J Clin Invest 116:2173-2182. 2006
    ..Thus in chronic lung diseases associated with increased adenosine, antagonism of A2BAR-mediated responses may prove to be a beneficial therapy...
  9. ncbi request reprint Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists
    Ming Yang
    Department of Pharmacology, CV Therapeutics, Inc, Palo Alto, CA 94304, USA
    Naunyn Schmiedebergs Arch Pharmacol 375:133-44. 2007
    ..Among the six A2A-antagonists, KW-6002 is the best for use in in vivo animal studies, particularly for a CNS target, based on its bioavailability, half life, and brain penetration...
  10. ncbi request reprint A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents
    Arvinder K Dhalla
    Department of Pharmacological Sciences, CV Therapeutics, Palo Alto, California, USA
    Am J Physiol Endocrinol Metab 292:E1358-63. 2007
    ..01) increased glucose infusion rate to values similar to that for chow-fed mice. In conclusion, CVT-3619 treatment lowers FFA and TG concentrations and improves insulin sensitivity in rodent models of insulin resistance...
  11. ncbi request reprint Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid
    Arvinder K Dhalla
    Department of Pharmacology, CV Therapeutics, Inc, 3172 Porter Drive, Palo Alto, CA 94304, USA
    J Pharmacol Exp Ther 321:327-33. 2007
    ..5 mg/kg). In summary, CVT-3619 is an orally bioavailable A1 agonist that lowers circulating FFA and TG levels by inhibiting lipolysis. CVT-3619 has antilipolytic effects at doses that do not elicit cardiovascular effects...
  12. ncbi request reprint A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion
    Peipei Wang
    Division of Cardiovascular Disease, Department of Medicine, University of Alabama, Birmingham, AL 35294 0005, USA
    J Pharmacol Exp Ther 321:213-20. 2007
    ....
  13. ncbi request reprint Effect of a specific and selective A(2B) adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma
    S Jamal Mustafa
    Department of Physiology and Pharmacology, School of Medicine, West Virginia University, Morgantown, WV 26506, USA
    J Pharmacol Exp Ther 320:1246-51. 2007
    ..These results suggest that A(2B)AR antagonism plays an important role in inhibition of airway reactivity and inflammation in this model of allergic asthma...
  14. ncbi request reprint CVT-4325 inhibits myocardial fatty acid uptake and improves left ventricular systolic function without increasing myocardial oxygen consumption in dogs with chronic heart failure
    Makoto Imai
    Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute, Detroit, MI, USA
    Cardiovasc Drugs Ther 21:9-15. 2007
    ..In the present study, we tested the hemodynamic and metabolic effects of acute intravenous CVT-4325 in dogs with HF...
  15. ncbi request reprint Ranolazine, a novel anti-anginal agent, does not alter isosorbide dinitrate- or sildenafil-induced changes in blood pressure in conscious dogs
    Gong Zhao
    CV Therapeutics, Inc, Palo Alto, CA 94304, USA
    Eur J Pharmacol 541:171-6. 2006
    ....
  16. ncbi request reprint A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers
    Toufigh Gordi
    CV Therapeutics Inc, Palo Alto, CA 94304, USA
    Clin Pharmacokinet 45:1201-12. 2006
    ..The aims of this study were to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of regadenoson (CVT-3146) in healthy, male volunteers...
  17. ncbi request reprint Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts
    Heather Fraser
    CV Therapeutics Inc, Palo Alto, CA 94304, USA
    J Mol Cell Cardiol 41:1031-8. 2006
    ..The beneficial effects of ranolazine in reducing Ca2+ overload and LV mechanical dysfunction during ischemia/reperfusion is consistent with the inhibition of late INa mechanism of action...
  18. ncbi request reprint A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-alpha increase
    Hongyan Zhong
    CV Therapeutics, Inc, 3172 Porter Drive, Palo Alto, CA 94304, USA
    Am J Respir Cell Mol Biol 35:587-92. 2006
    ..The results of this study suggest that there is a novel pathway whereby adenosine can initiate and amplify an inflammatory response which might be important in pathogenesis of inflammatory lung diseases...
  19. pmc Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine
    Serge Sicouri
    Masonic Medical Research Laboratory, Utica, New York 13501 1787, USA
    Heart Rhythm 4:638-47. 2007
    ..2 resulting in gain of function of the L-type calcium current (I(Ca,L)). Ranolazine is an antianginal agent shown to exert an antiarrhythmic effect in experimental models of long QT syndrome...
  20. ncbi request reprint Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist
    Gong Zhao
    Department of Pharmacology and Preclinical Development, CV Therapeutics, Inc, Palo Alto, California, USA
    J Cardiovasc Pharmacol 49:369-75. 2007
    ..The results indicate that 1 to 10 mg/kg caffeine dose-dependently reduced the duration, but not the peak increase of CBF caused by 5 microg/kg regadenoson...
  21. doi request reprint Late sodium current inhibition as a new cardioprotective approach
    Sharon L Hale
    The Heart Institute of Good Samaritan Hospital, Los Angeles, CA 90017, USA
    J Mol Cell Cardiol 44:954-67. 2008
    ..This article reviews published data describing the role of late sodium current and its inhibition by ranolazine in clinical and experimental studies of myocardial ischemia...
  22. doi request reprint Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation
    Samuel Sossalla
    Heart Center, Georg August University Gottingen, Germany
    J Mol Cell Cardiol 45:32-43. 2008
    ..These results suggest that ranolazine may be of therapeutic benefit in conditions of diastolic dysfunction due to elevated [Na(+)](i) and diastolic [Ca(2+)](i)...
  23. doi request reprint A novel partial fatty acid oxidation inhibitor decreases myocardial oxygen consumption and improves cardiac efficiency in demand-induced ischemic heart
    Lin Wu
    Department of Pharmacological Sciences, CV Therapeutics, Inc, Palo Alto, CA 94304, USA
    J Cardiovasc Pharmacol 51:372-9. 2008
    ..05 +/- 0.01 mM (P < 0.01). Thus, the FOX inhibitor CVT-4325 decreased MVO2 and increased myocardial efficiency during demand-(pacing)-induced ischemia in the presence of palmitate in the rodent isolated hearts...
  24. pmc Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation
    Alexander Burashnikov
    Masonic Medical Research Laboratory, 2150 Bleecker Street, Utica, NY 13501, USA
    Ann N Y Acad Sci 1123:105-12. 2008
    ..Our findings suggest that atrial-selective sodium channel block may be a valuable strategy to combat AF...
  25. doi request reprint Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits
    Wei Qun Wang
    Department of Pharmacological Sciences, CV Therapeutics, Inc, 3172 Porter Drive, Palo Alto, CA 94304, USA
    J Pharmacol Exp Ther 325:875-81. 2008
    ..We conclude that ranolazine antagonizes the ventricular repolarization changes caused by clofilium and suppresses clofilium-induced TdP in rabbits...
  26. doi request reprint An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes
    Yejia Song
    Division of Cardiovascular Medicine, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610 0277, USA
    Am J Physiol Heart Circ Physiol 294:H2031-9. 2008
    ..The data reveal that an increase of late I(Na) is a novel mechanism for initiation of atrial arrhythmic activity...
  27. pmc Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone
    Lin Wu
    Department of Pharmacological Sciences, CV Therapeutics, Inc 3172 Porter Drive, Palo Alto, CA 94304, USA
    Cardiovasc Res 77:481-8. 2008
    ..The objective of this study was to reveal and explain the pro- and anti-arrhythmic effects of acute exposure to amiodarone in an animal model...
  28. ncbi request reprint Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial
    Ami E Iskandrian
    University of Alabama at Birmingham, Birmingham, AL 35294 0006, USA
    J Nucl Cardiol 14:645-58. 2007
    ..Earlier phase 1 and 2 studies have shown that regadenoson has desirable features as a stress agent for myocardial perfusion imaging...
  29. ncbi request reprint Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischem
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:1647-52. 2007
    ..Ranolazine reduces proarrhythmic substrate and triggers such as early afterdepolarization in experimental models. However, the potential antiarrhythmic actions of ranolazine have yet to be demonstrated in humans...
  30. pmc Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine
    Alexander Burashnikov
    Masonic Medical Research Laboratory, Utica, NY 13501, USA
    Circulation 116:1449-57. 2007
    ..The development of selective atrial antiarrhythmic agents is a current strategy for suppression of atrial fibrillation (AF)...
  31. pmc Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations
    Serge Sicouri
    Masonic Medical Research Laboratory, Utica, New York 13501, USA
    Heart Rhythm 5:1019-26. 2008
    ..Ectopic activity arising from the pulmonary veins (PV) plays a prominent role in the development of atrial fibrillation (AF)...
  32. ncbi request reprint Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans
    Hsiao D Lieu
    Portola Pharmaceuticals, South San Francisco, Calif, USA
    J Nucl Cardiol 14:514-20. 2007
    ..This study characterized the dose dependence of regadenoson-induced coronary hyperemia...
  33. doi request reprint Rapid kinetic interactions of ranolazine with HERG K+ current
    Sridharan Rajamani
    Department of Pharmacological Sciences, CV Therapeutics, Inc, Palo Alto, California 94304, USA
    J Cardiovasc Pharmacol 51:581-9. 2008
    ..These distinct and rapid kinetic interactions of ranolazine with IHERG may partially contribute to the observations that the drug is not proarrhythmic despite causing a small prolongation of action potentials and QT intervals...
  34. pmc The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis
    Charles Antzelevitch
    Masonic Medical Research Laboratory, Utica, New York, NY 13501, USA
    J Cardiovasc Electrophysiol 17:S79-S85. 2006
    ....
  35. ncbi request reprint Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs
    Gong Zhao
    CV Therapeutics, Inc, Palo Alto, CA 94304, USA
    J Pharmacol Exp Ther 307:182-9. 2003
    ..Furthermore, CVT-3146 did not cause renal vasoconstriction. These features make CVT-3146 a better candidate for pharmacologic stress testing...
  36. ncbi request reprint Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation
    Jose M Di Diego
    Masonic Medical Research Laboratory, 2150 Bleecker St, Utica, NY 13501 1787, USA
    Circulation 108:1027-33. 2003
    ..The present study examines the electrophysiological actions of cisapride in the isolated arterially perfused canine left ventricular wedge preparation...
  37. ncbi request reprint A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells
    Hongyan Zhong
    CV Therapeutics, Inc, 3172 Porter Drive, Palo Alto, CA 94304, USA
    Am J Respir Cell Mol Biol 30:118-25. 2004
    ..Our findings provide a novel mechanism whereby Ado acts as a proinflammatory mediator in the airway...
  38. ncbi request reprint N-[3-(R)-tetrahydrofuranyl]-6-aminopurine riboside, an A1 adenosine receptor agonist, antagonizes catecholamine-induced lipolysis without cardiovascular effects in awake rats
    Heather Fraser
    CV Therapeutics, Palo Alto, California 94304, USA
    J Pharmacol Exp Ther 305:225-31. 2003
    ....
  39. ncbi request reprint Pharmacology and therapeutic applications of A1 adenosine receptor ligands
    Arvinder K Dhalla
    Department of Drug Research and Pharmacological Sciences, CV Therapeutics Inc Palo Alto, CA 94304, USA
    Curr Top Med Chem 3:369-85. 2003
    ..Antagonists of the A(1) receptor can increase urine formation, and because they do not decrease renal blood flow, are particularly useful to maintain glomerular filtration in patients having edema secondary to reduced cardiac function...
  40. ncbi request reprint Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging
    Jean Noel Trochu
    Department of Physiology, New York Medical College, Valhalla, New York 10595, USA
    J Cardiovasc Pharmacol 41:132-9. 2003
    ....
  41. ncbi request reprint Potentiation of the negative dromotropic effect of adenosine by rapid heart rates: possible ionic mechanism
    Anatoly E Martynyuk
    Department of Anesthesiology, University of Florida, Gainesville, Florida 32610 0254, USA
    Basic Res Cardiol 97:295-304. 2002
    ....
  42. ncbi request reprint Contribution of I(K,ADO) to the negative dromotropic effect of adenosine
    Anatoly E Martynyuk
    Department of Anesthesiology, University of Florida, Gainesville, Florida 32610 0254, USA
    Basic Res Cardiol 97:286-94. 2002
    ..Therefore, we studied the contribution of I(K,ADO) to the negative dromotropic effect of adenosine...
  43. ncbi request reprint Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation
    Igor Feoktistov
    Division of Cardiology, Vanderbilt University, Nashville, Tenn 37232 6300, USA
    Circ Res 90:531-8. 2002
    ..A2B receptors, predominantly expressed in human microvascular cells, modulate expression of angiogenic factors via coupling to G(q), and possibly via G12/13...
  44. pmc Tonic activity of the rat adipocyte A1-adenosine receptor
    Hui Xiu Liang
    Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, Florida, FL 32610, USA
    Br J Pharmacol 135:1457-66. 2002
    ..Adipocytes may be a model for cells whose functions are tonically modulated by adenosine present in the interstitium of well-oxygenated tissues...
  45. ncbi request reprint Age-dependent atrial remodeling induced by recombinant human interleukin-11: implications for atrial flutter/fibrillation
    Jiang Xu
    MCP Hahnemann University, Philadelphia, Pennsylvania 19102 1192, USA
    J Cardiovasc Pharmacol 39:435-40. 2002
    ..It was concluded that rhIL-11 induces age-dependent atrial remodeling manifested by atrial stretch and reduced atrial refractoriness, which favor AF. Na retention is the most likely mechanism underlying this effect of rhIL-11...
  46. ncbi request reprint Does recombinant human interleukin-11 exert direct electrophysiologic effects on single human atrial myocytes?
    Laura Sartiani
    Center of Molecular Medicine CIMMBA and Department of Preclinical and Clinical Pharmacology, University of Firenze, Italy
    J Cardiovasc Pharmacol 39:425-34. 2002
    ..Thus, it is unlikely that direct alterations of membrane potential and currents of HuAM caused by rhIL-11 are the basis for the genesis of atrial arrhythmias observed in patients treated with this agent...
  47. ncbi request reprint Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome
    Lin Wu
    CV Therapeutics, Inc, Palo Alto, California
    J Pharmacol Exp Ther 310:599-605. 2004
    ..Thus, although ranolazine alone prolonged APD, it reduced APD and ventricular arrhythmias caused by agents that increased late I(Na) and decreased I(K)...
  48. ncbi request reprint Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF)
    Jeff A Zablocki
    CV Therapeutics, Inc, 3172 Porter Dr, Palo Alto, CA 94304, USA
    Curr Top Med Chem 4:839-54. 2004
    ..To meet these challenges, further medicinal chemistry efforts in the area of partial A(1)-adenosine receptor agonism are still needed...
  49. pmc Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current
    Albertas I Undrovinas
    Heart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan 48202 2689, USA
    J Cardiovasc Electrophysiol 17:S169-S177. 2006
    ....
  50. ncbi request reprint Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction
    Yejia Song
    Division of Cardiovascular Medicine, University of Florida, 1600 SW Archer Rd, M 411, Gainesville, FL 32610 0277, USA
    J Pharmacol Exp Ther 318:214-22. 2006
    ....
  51. ncbi request reprint A novel partial agonist of the A(1)-adenosine receptor and evidence of receptor homogeneity in adipocytes
    Marjan Fatholahi
    CV Therapeutics, Inc, 3172 Porter Drive, Palo Alto, CA 94304, USA
    J Pharmacol Exp Ther 317:676-84. 2006
    ..It was concluded that rat epididymal adipocyte A(1)AdoR are a homogeneous receptor population with regard to affinities for ligands and that CVT-3619 is a partial agonist with selectivity for A(1)AdoR and inhibition of lipolysis...
  52. ncbi request reprint An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts
    Lin Wu
    Pharmacological Sciences, CV Therapeutics, Inc, Palo Alto, CA 94304, USA
    J Pharmacol Exp Ther 316:718-26. 2006
    ..Thus, in the female rabbit heart, ATX-II potentiated the effects of QT-prolonging drugs to increase MAPD(90) and unmasked the proarrhythmic activities of these drugs at clinically relevant drug concentrations...
  53. ncbi request reprint Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats
    Arvinder K Dhalla
    Department of Pharmacology, CV Therapeutics, Palo Alto, CA 94304, USA
    J Pharmacol Exp Ther 316:695-702. 2006
    ....
  54. ncbi request reprint Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson
    Kenneth A Ellenbogen
    Medical College of Virginia, Richmond, VA 23298 0053, USA
    Circulation 111:3202-8. 2005
    ..This trial was designed to determine a safe and effective tecadenoson bolus for termination of electrophysiologically induced PSVT...
  55. ncbi request reprint A mechanistic approach to assess the proarrhythmic risk of QT-prolonging drugs in preclinical pharmacologic studies
    John C Shryock
    Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, USA
    J Electrocardiol 37:34-9. 2004
    ..However, the assays described herein are capable of detecting the proarrhythmic effects of currently used drugs, even when these effects are reported to be extremely rare in clinical practice...
  56. ncbi request reprint Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent
    Charles Antzelevitch
    Masonic Medical Research Laboratory, Utica, NY 13501, USA
    J Cardiovasc Pharmacol Ther 9:S65-83. 2004
    ..Ranolazine's actions to reduce TDR and suppress early after depolarization suggest that in addition to its anti-anginal actions, the drug possesses antiarrhythmic activity...
  57. pmc Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties
    Charles Antzelevitch
    Masonic Medical Research Laboratory, 2150 Bleecker St, Utica, NY 13501, USA
    Circulation 110:904-10. 2004
    ..The present study examines its electrophysiological effects in isolated canine ventricular myocytes, tissues, and arterially perfused left ventricular wedge preparations...
  58. pmc Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects
    Gernot Schram
    Department of Medicine, Research Center, Montreal Heart Institute, Quebec, Canada
    Br J Pharmacol 142:1300-8. 2004
    ..The greater safety of ranolazine may be due to its ability to inhibit I(Ca) at concentrations only slightly larger than those that inhibit I(Kr), thus producing offsetting effects on repolarization...
  59. ncbi request reprint Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes
    Yejia Song
    Division of Cardiovascular Medicine, University of Florida, Gainesville, 32610, USA
    J Cardiovasc Pharmacol 44:192-9. 2004
    ..The results demonstrate that ranolazine reduces late INa and has an anti-arrhythmic effect when late INa is increased...
  60. ncbi request reprint Selective attenuation of isoproterenol-stimulated arrhythmic activity by a partial agonist of adenosine A1 receptor
    Yejia Song
    Department of Medicine, University of Florida, Gainesville, FL 32610, USA
    Circulation 105:118-23. 2002
    ..The goal of this study was to examine the hypothesis that a partial agonist of the adenosine A1 receptor (A1AdoR) may cause a greater attenuation of catecholamine-induced ventricular arrhythmic activity than of contractility...
  61. ncbi request reprint Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts
    Hongyan Zhong
    Department of Drug Research and Pharmacological Sciences, CV Therapeutics, Inc, 3172 Porter Drive, Palo Alto, CA 94304, USA
    Am J Respir Cell Mol Biol 32:2-8. 2005
    ..Our findings provide a novel mechanism whereby adenosine participates in the remodeling process of inflammatory lung diseases...
  62. ncbi request reprint Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist
    Eric N Prystowsky
    Care Group, Indianapolis, Indiana 46260, USA
    J Am Coll Cardiol 42:1098-102. 2003
    ..The aim of this study was to evaluate tecadenoson safety and efficacy during conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm...